Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FSU76
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,273
Award facts
- Contract value 100% obligated
- $10,273.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Xolair 300 mg/2 mL auto-injectors valued at $10,273.38. The delivery order, awarded on October 23, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to support the Department of Defense's pharmaceutical supply needs across military healthcare facilities worldwide.
DMS Pharmaceutical Group's established performance on this delivery order reflects its critical role as a regional prime vendor contractor within the PPV-G GEN V framework, which features a $499,999,999 ceiling value and an ultimate completion date of December 31, 2036. The contractor's comprehensive product portfolio spans branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, positioning it as a key supplier for recurring medical supply requirements of the military healthcare system. The company's demonstrated capability to distribute diverse pharmaceutical products, including immunosuppressants such as Xolair, across Department of Defense facilities underscores its significance within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FSU76?
SPE2DB26FSU76 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FSU76 worth?
The government has obligated $10,273 on SPE2DB26FSU76.
Is contract SPE2DB26FSU76 an order under another contract?
Yes. SPE2DB26FSU76 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSU76 competed?
The extent of competition for SPE2DB26FSU76 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award